![Razan Mohty: Metanalysis on role of alloHCT in VEXAS syndrome](https://oncodaily.com/pub/uploads/2024/07/Razan-Mohty-e1722431340748.png)
Photo taken from Razan Mohty/X
Jul 31, 2024, 11:15
Razan Mohty: Metanalysis on role of alloHCT in VEXAS syndrome
Razan Mohty, Assistant Professor at UAB Medicine, O’Neal Comprehensive Cancer Center, made the following announcement on Twitter:
“Check our metanalysis on role of alloHCT in VEXAS syndrome published in Bone Marrow Transplantation Journal
alloHCT is an effective treatment for patients with VEXAS syndrome.
‘Assessing the efficacy of allogeneic hematopoietic cell transplantation in VEXAS syndrome: results of a systematic review and meta-analysis’
Authors: Razan Mohty, Tea Reljic, Nayef Abdel-Razeq, Omer Jamy, Talha Badar, Ambuj Kumar, Mahmoud Aljurf & Mohamed A. Kharfan-Dabaja.”
Source: Razan Mohty/X